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Abstract
Background: The metabolic syndrome (MetS) is associated with the presence of low grade inflammation. Our aim
was to analyze the inter-relations between each of the components of the metabolic syndrome (MetS) and four
inflammatory markers, namely high sensitivity C-reactive protein (hs-CRP), the erythrocyte sedimentation rate, the
concentration of fibrinogen and the white blood cell count.
Methods: We have analyzed data collected between September 2002 and June 2009 in the Tel-Aviv medical
center inflammation survey (TAMCIS). We recruited both apparently healthy individuals and individuals presenting
with atherothrombotic risk factors. All participants were enrolled during their routine annual health check-up and
gave their written informed consent. This is a cross sectional study in which we have fitted linear regression
models using inflammatory markers as the dependant variables and adjust them according to the different
components of the MetS and multiple other confounders.
Results: Included were 12,072 individuals of whom there were 7,760 men at a mean (S.D.) age of 44 (11) years,
and 4,312 women aged 44 (11) years. A significant correlation was noted between most components of the MetS
and all inflammatory markers, the most significant one being with hs-CRP. In the multi-adjusted regression analysis,
waist was the factor that best explained the variability of hs-CRP, in both women and men. It also remained a
significant variable for the other inflammatory markers.
Conclusions: From amongst the various components of the MetS, waist circumference appears to exert the most
influence upon the presence and intensity of the micro-inflammatory response.
Background
The metabolic syndrome (MetS) is associated with the
presence of a low grade sub-clinical inflammatory pro-
cess, so called micro-inflammation [1-7]. The relation-
ship between this process and the risk of insulin
resistance development, a hallmark of the MetS,[7-9] as
well as the risk of cardiovascular morbidity and mortality,
[10-12] has been previously described. Therefore, it
was suggested that the detection and quantification of
micro-inflammation in patients with the MetS might be
of clinical relevance [13]. Whilst most studies have used
the highly sensitive C-reactive protein (hs-CRP) assay for
the detection and quantification of micro-inflammation
other commonly used and established markers might be
also relevant. These include the Westergren erythrocyte
sedimentation rate (ESR),[14] the white blood cell count
(WBCC),[15] and quantitative fibrinogen concentrations
[16].
In order to evaluate the contribution of the MetS
components (elevated waist circumference, low high-
density lipoprotein, high triglycerides, impaired fasting
glucose and elevated blood pressure) to the micro-
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analyzed the strength of the association between each
MetS component and four established inflammatory
markers. The relative influence of the components of
the MetS on these inflammatory markers may be of
clinical significance aiding in the establishment of clini-
cal guidelines for health care providers as well to public
health policy makers.
Methods
Study Population
In the present study we analyzed the data collected at
the Tel-Aviv Medical Center Inflammation Survey
(TAMCIS), a registered data bank of the Israeli Ministry
of Justice [17-20]. This is a relatively large survey com-
prising of apparently healthy individuals attending a
center for periodic health examinations. Subjects attend-
ing the center for a routine health examination between
September 2002 and June 2009 were invited to partici-
pate in the TAMCIS. We recruited both apparently
healthy individuals and individuals presenting with
atherothrombotic risk factors. All the individuals who
were enrolled were recruited during their routine annual
health check-up and gave their written consent in accor-
dance with the guidelines of the institutional ethics
committee. A total of 15,605 subjects gave their
informed consent (9,881 males, 5,724 females). Later,
2,797 subjects were excluded from the analysis due to
any malignancy, immunosuppressive therapy, known
inflammatory disease (arthritis, inflammatory bowel dis-
ease, psoriasis, etc.), pregnancy, steroidal or non-
steroidal treatment (except for aspirin at a dose of ≤ 325
mg/day), acute infection or invasive procedures (surgery,
catheterization, etc.) during the last 6 months. An addi-
tional 168 subjects were further excluded because they
had no recorded hs-CRP values. The chance that dia-
betics harbor multiple additional inflammatory confoun-
ders such as use of statins[21] and anti-hyperglycemic
medications[22-24], hidden infections[25], and yet unde-
termined inflammatory mechanisms[26] is high. There-
fore, we have decided to narrow the scope of our
analysis by excluding diabetics, including any individual
taking medications for diabetes. Thus, 568 individuals
were finally excluded due to a suspected or confirmed
diagnosis of diabetes mellitus. Following these exclu-
sions the study group comprised of 12,072 individuals
(7,760 males and 4,312 females). These were all people
visiting for the first time.
Laboratory Methods
Blood samples were drawn in the morning hours, after a
12-h overnight fast. The WBCC and differential were
performed using the Coulter STKS (Beckman Coulter,
Nyon, Swiss) electronic analyzer, while fibrinogen
concentrations were determined by the method of
Clauss[27] and a Sysmax 6000 (Sysmex Corporation,
Hyaga, Japan) analyzer. High sensitivity C-Reaeactive
protein concentrations were determined by using the
Behring BN II Nephelometer (DADE Behring, Marburg,
Germany) analyzer and a method described according to
Rifai et al. [28]. Glucose, triglycerides and high density
lipoprotein cholesterol were measured using a Bayer
Advia 1650 chemistry analyzer and Bayer respective kits
(Bayer healthcare diagnostics division, Newbury, UK).
Definition Of Atherothrombotic Risk Factors
The results of the routine health check-up were evalu-
ated by employing certain definitions of the various
atherothrombotic risk factors. Diabetes mellitus was
defined as a fasting blood glucose level of ≥ 126 mg/dl
(7 mmol/L) or treatment with insulin or oral hypoglyce-
mic medications. Hypertension was defined as displaying
with blood pressure of ≥ 140/90 mmHg in two separate
measurements or the intake of anti-hypertensive medi-
cations. Dyslipidemia was defined as the low density
lipoprotein cholesterol (LDL-C) or non- high density
lipoprotein cholesterol (non-HDL-C) concentrations, for
individuals displaying elevated triglyceride concentra-
tions of ≥ 200 mg/dl (2.26 mmol/l) above the recom-
mended levels, according to the risk profile defined by
the updated adult treatment panel III (ATP III) recom-
mendations[29], or the intake of lipid lowering medica-
tions. The Diagnosis of the Metabolic Syndrome was
based on the National cholesterol education program
ATP III Criteria [29]. The criteria for impaired fasting
glucose is that used by the American Diabetes Associa-
tion [30] as proposed by the updated American Heart
Association/National Heart, Lung, and Blood Institute
scientific statement [31]. In summary, elevated waist cir-
cumference was defined as ≥ 102 cm (40 inches) in men
and ≥ 88 (35 inches) in women; Elevated triglycerides
were defined as ≥ 150 mg/dl (1.7 mmol/l) or a person
receiving drug treatment for elevated triglycerides;
Reduced HDL-C was defined as ≤ 40 mg/dL (1.03
mmol/l) in men and ≤ 50 mg/dl (1.3 mmol/l) in women
or a person receiving drug treatment for reduced HDL-
C; Elevated blood pressure was defined as ≥ 130 mm Hg
systolic blood pressure or ≥ 85 mm Hg diastolic blood
pressure or a person receiving antihypertensive drug
treatment; Elevated fasting glucose was defined as ≥ 100
mg/dl. Smokers were defined as individuals who smoked
at least 5 cigarettes per day while past smokers had
stopped smoking for at least 30 days prior to examina-
tion. Measured waist circumference was defined accord-
ing to the National cholesterol education program’s
ATP III guidelines [29]. To measure the waist circum-
ference, we located the top of the right iliac crest, placed
a measuring tape in a horizontal plane around the
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Measurements were made at the end of a normal
expiration.
Statistical Methods
All data was summarized and displayed as mean ±
standard deviation (SD) for the continuous variables
and as number of patients plus the percentage in each
group for categorical variables. Since hs-CRP, ESR and
the triglyceride concentrations display irregular distri-
butions, we used a logarithmic transformation which
converted the distributions to normal ones for all sta-
tistical procedures. Therefore, all results of hs-CRP,
ESR or triglyceride concentrations are expressed as
back transformed geometrical means and standard
deviations. The One-Way Kolmogorov-Smirnov test
was used to assess the distributions. For all categorical
variables the Chi-Square statistic was used to assess
the statistical significance between the two genders.
Pearson partial correlations for confounding variables
were used to evaluate the age adjusted association
between the various components of the MetS and the
inflammatory variables. In order to assess and compare
the contribution of the different components of the
MetS to the variability of the various inflammatory
variables, we used linear regression models. The
inflammatory variables were the dependent variables
and the different components of the MetS, as well as
other potential confounders, were the covariates. The
confounders included age, history of proven athero-
thrombotic disease (myocardial infarction, coronary
artery bypass graft surgery, cerebrovascular event or
peripheral artery occlusion disease), smoking status,
alcohol consumption, level of physical activity and
medication with potential influence on the inflamma-
tory markers and/or the metabolic components such as
angiotensin converting enzyme (ACE) inhibitors,
angiotensin II receptor blockers, statins, fibrates and
aspirin, as well as hormone replacement therapy or
oral contraceptives in females. In an attempt to adjust
for the association between the inflammatory variables
(mainly hs-CRP) and obesity, we repeated the correla-
tions and the linear regression models with additional
adjustment for BMI. All above analyses were consid-
ered significant at p < 0.05 (two tailed). The statistical
package for the Social Sciences (SPSS) was used to
perform all statistical evaluation (SSPS Inc., Chicago,
IL, USA).
Results
We have presently analyzed a total of 7,760 men at a
mean (S.D.) age of 44 (11) years (range 18-83) and 4,312
women aged 44 (11) years (range 18-77). The frequencies
of the different components per each participant are
d e s c r i b e di nT a b l e1 .I tc a nb es e e nt h a tt h ed i f f e r e n t
components of the MetS differ significantly between the
two genders. The age adjusted Pearson partial coeffi-
cients of correlations between the number of MetS com-
ponents and each component of MetS and between the
inflammatory markers are shown in Table 2, for both
genders. The hs-CRP concentrations correlated signifi-
cantly with all components of the MetS in both genders.
A relatively high correlation between waist and the
inflammatory markers was found. The results of
the regression analysis are reported in Table 3. Waist was
the variable that explained most of the variability of hs-
CRP, ESR and fibrinogen in both women and men. It
remained significant also for the WBCC in both genders,
but as the second most predominant contributing factor.
We repeated our correlation and regression analyses
making additional adjustments for BMI (data not shown).
As expected, all the correlation coefficients were smaller
compared to the previous analyses. Despite this, in most
c a s e st h er e s u l t sr e m a i n e ds i g n i f i c a n t .A sb e f o r e ,w a i s t
circumference showed the highest partial correlations in
comparison to the other variables. Adjustment for BMI
decreased all correlations, but the decline was more pro-
nounced in females compared to males.
Discussion
The present analysis has shown that amongst the var-
ious components of the MetS, waist circumference is
the component that most significantly influences the
micro-inflammatory response. Invariably, Waist and
BMI are used inter-changeably in the definition of the
Table 1 Frequency of the different metabolic syndrome
components among the cohort
Men Women Chi-square
Significance
(N = 7,760) (N = 4,312)
N % N. %
Waist circumference 1,490 19.2 1,037 24.0 < 0.001
HDL 901 11.6 642 14.9 < 0.001
Triglycerides 1,889 24.3 581 13.5 < 0.001
IFG 1,390 17.9 494 11.5 < 0.001
Elevated blood
pressure
3,090 39.8 1,031 23.9 < 0.001
Zero Components 2,765 35.6 2,107 48.9
One Component 2,511 32.4 1,194 27.7
Two Components 1,512 19.5 590 13.7 < 0.001
Metabolic Syndrome 972 12.5 421 9.8
(Three or more
Components)
* Criteria for the metabolic syndrome components are defined in the text.
**abbreviations: HDL = high density lipoprotein, IFG = impaired fasting
glucose.
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inflammatory biomarkers
Men
(N = 7,760)
Number of Components Waist HDL TG Glucose DBP SBP
Log(hs-CRP) 0.262
§ 0.345
§ -0.197
§ 0.191
§ 0.082
§ 0.131
§ 0.083
§
Log(ESR) 0.080
§ 0.118
§ -0.092
§ 0.082
§ 0.015 0.018 -0.005
Fibrinogen 0.102
§ 0.170
§ -0.092
§ 0.063
§ 0.037
§ 0.070
§ 0.017
WBCC 0.189
§ 0.182
§ -0.128
§ 0.216
§ 0.006 0.108
§ 0.099
§
Women
(N = 4,312)
Number of Components Waist HDL TG Glucose DBP SBP
Log(hs-CRP) 0.362
§ 0.405
§ -0.151
§ 0.379
§ 0.143
§ 0.186
§ 0.198
§
Log(ESR) 0.126
§ 0.169
§ -0.090
§ 0.136
§ 0.050
§ 0.052
§ 0.049
§
Fibrinogen 0.171
§ 0.253
§ -0.082
§ 0.142
§ 0.037
‡ 0.106
§ 0.091
§
WBCC 0.216
§ 0.163
§ -0.128
§ 0.258
§ 0.043
‡ 0.096
§ 0.113
§
* Criteria for the metabolic syndrome components are defined in the text.
**Abbreviations: hs-CRP = high sensitivity C-reactive protein; ESR = erythrocyte sedimentation rate; WBCC = white blood cell count; HDL = high density
lipoprotein; TG = triglycerides; DBP = diastolic blood pressure, SBP = systolic blood pressure.
***‡ - 0.01 < P < 0.05; § - P < 0.01
Table 3 Metabolic syndrome components ordered according to the strength of the association to each inflammatory
biomarker
Inflammatory variable Gender Variable Non-standardized Coefficients Significance Partial Correlation
B S.E.
Log(hs-CRP) Men Waist 0.013 0.001 < 0.001 0.274
(R
2 = 0.17) HDL -0.004 0.001 < 0.001 -0.095
Log(TG) 0.111 0.026 < 0.001 0.052
DBP 0.003 0.001 0.002 0.038
Glucose 0.001 0.001 0.045 0.024
SBP 0.000 0.001 0.571 -0.007
(R
2 = 0.33) Women Waist 0.016 0.001 < 0.001 0.331
Log(TG) 0.459 0.038 < 0.001 0.189
HDL -0.002 0.001 < 0.001 -0.057
Glucose 0.002 0.001 0.062 0.030
SBP 0.001 0.001 0.104 0.026
DBP 0.001 0.001 0.382 0.014
Log(ESR) Men Waist 0.003 < 0.001 < 0.001 0.091
(R
2 = 0.07) HDL -0.002 < 0.001 < 0.001 -0.045
Log(TG) 0.062 0.021 0.003 0.037
SBP < 0.001 < 0.001 0.059 -0.024
Glucose < 0.001 < 0.001 0.689 -0.005
DBP < 0.001 0.001 0.584 0.007
(R
2 = 0.07) Women Waist 0.003 < 0.001 < 0.001 0.114
Log(TG) 0.105 0.024 < 0.001 0.072
HDL < 0.001 < 0.001 0.100 -0.027
SBP < 0.001 < 0.001 0.370 -0.015
Glucose < 0.001 0.001 0.507 -0.011
DBP < 0.001 0.001 0.746 0.005
Fibrinogen Men Waist 0.873 0.074 < 0.001 0.141
(R
2 = 0.14) DBP 0.560 0.116 < 0.001 0.059
HDL -0.250 0.070 < 0.001 -0.043
SBP -0.210 0.067 0.002 -0.038
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ciation between them. Due to this association, adjusting
for waist and BMI together causes problematic co-
linearity. However, it must be noted that waist circum-
ference still remained the most significant predictor of
t h ei n f l a m m a t o r yr e s p o n s ee v e n after additional adjust-
ment for BMI. There is a known association between
the MetS and the presence of micro-inflammation
[32-34] but to the best of our knowledge, the relative
contribution of the different MetS components to the
low grade, sub-clinical inflammatory response has not
been previously evaluated. Thus, our findings contribute
original information to the literature being the largest
analysis to date evaluating the association between
inflammation and each individual component of the
metabolic syndrome in adults. A previous analysis from
our group regarding the hypertriglyceridemic waist phe-
notype, evaluated this phenotype and its relation to
inflammation [35]. This phenotype however, although
related to the metabolic syndrome, has different defini-
tions from the metabolic syndrome. The previous work
evaluated this difference and did not analyze the relative
weight of each component of the metabolic syndrome.
The importance of the current analysis stems from the
detrimental effect that the presence of micro-inflamma-
tion has on the pathogenesis of atherothrombosis, insu-
lin resistance, [7,9] and cardiovascular morbidity and
mortality [10-12]. This study has analyzed commonly
used inflammatory markers with known atherosclerotic
significance. High sensitivity C-reactive protein has been
shown to have deleterious effects on vascular biology,
[33] white blood cells can contribute to endothelial
injury[36] and fibrinogen is related to hyperviscosity,
which in turn can also contribute to vascular events
[37]. Thus, the presence of these markers could repre-
sent a link between the individual components of the
MetS and the development of the atherosclerotic
disease.
The prevalence of the MetS in our cohort was relatively
low. In fact only 9.6% of women and 11.7% of men had
three MetS components or more. One possible explana-
tion for this is the fact that this study was performed in a
group of relatively healthy individuals. However, this
population could represent those individuals that are still
not affected by the results of long standing atherosclero-
t i cd i s e a s ea n dm i g h tt h e r e f o r eb e n e f i tf r o mp r e v e n t i v e
Table 3: Metabolic syndrome components ordered according to the strength of the association to each inflammatory
biomarker (Continued)
Glucose 0.096 0.077 0.210 0.015
Log(TG) -3.648 3.364 0.278 -0.013
(R
2 = 0.12) Women Waist 1.282 0.095 < 0.001 0.214
DBP 0.363 0.181 0.045 0.032
Log(TG) 7.253 5.106 0.156 0.023
Glucose -0.157 0.110 0.153 -0.023
HDL -0.086 0.068 0.202 -0.021
SBP -0.103 0.100 0.303 -0.017
WBCC Men Log(TG) 1.153 0.097 < 0.001 0.146
(R
2 = 0.12) Waist 0.019 0.002 < 0.001 0.109
Glucose -0.008 0.002 0.001 -0.042
DBP 0.010 0.003 0.002 0.038
SBP 0.005 0.002 0.013 0.031
HDL -0.004 0.002 0.047 -0.025
(R
2 = 0.13) Women Log(TG) 1.604 0.147 < 0.001 0.177
Waist 0.012 0.003 < 0.001 0.071
HDL -0.005 0.002 0.011 -0.042
SBP 0.007 0.003 0.014 0.041
Glucose -0.004 0.003 0.180 -0.022
DBP 0.002 0.005 0.711 0.006
*Criteria for the metabolic syndrome components are defined in the text.
**All models were adjusted in addition to the different components of the MetS, to age, history of proven atherothrombotic disease, smoking status, alcohol
consumption, level of physical activity and medication such as ACE inhibitors, Angiotensin II receptor blockers, statins, fibrates and aspirin, as well as hormone
replacement therapy or oral contraceptives in females.
***Abbreviations: hs-CRP = high sensitivity C-reactive protein; ESR = erythrocyte sedimentation rate; WBCC = white blood cell count; HDL = high density
lipoprotein; TG = triglycerides; DBP = diastolic blood pressure, SBP = systolic blood pressure.
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did not limit ourselves to individuals with an established
diagnosis of MetS. We wanted to discover the relation-
ship between the presence of micro-inflammation and
changes in each individual component of the MetS, even
in individuals without defined MetS. Theoretically, our
findings can be used to support the recent report by Arn-
lov et al [38] that have demonstrated that overweight and
obese individuals without MetS are as well at an
increased risk for cardiovascular mortality and morbidity.
It is crucial to understand that preventative measures
should be implemented early, even when only one or two
components are present, since even a mild increase in
inflammation and the presence of one or two MetS com-
ponents can be associated with a significant increase in
future risk of MetS development. Our study is therefore
relevant not only for those individuals who meet all the
criteria of the MetS but even for individuals who are in a
pre-MetS state. Furthermore, the clinical importance of
our findings is also strengthened by the work of Ridker et
al. [12]. The Jupiter trial showed that statin therapy in
apparently healthy persons without hyperlipidemia but
with elevated C-reactive protein levels significantly
reduced the incidence of major cardiovascular events.
Thus, elevated waist circumference as the primary contri-
butor of the inflammatory state in the MetS, could by
itself in the future be a possible indication for statin ther-
apy [39].
In conclusion, a clarification of the relationship
between each MetS component and the intensity of the
micro-inflammatory response may be of clinical rele-
vance. Such a clarification might help to highlight the
importance of targeted interventions such as weight
reduction, a measure previously proved to be clearly
beneficial [40,41].
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